clinical trial · NCT05583552
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
GCP-Service International West GmbH·phase2·active not recruiting·n = 46
Myelodysplastic SyndromesAcute Myeloid LeukemiaImetelstat sodium
brief summary
The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.
started
Jun 5, 2023
primary completion
Sep 30, 2025
completion
Jun 1, 2026
last updated
Mar 14, 2025
official title
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol